{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T15:11:45Z","timestamp":1791472305824,"version":"4.3.4"},"reference-count":38,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2023,11,25]],"date-time":"2023-11-25T00:00:00Z","timestamp":1700870400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"Spogards Fond"},{"DOI":"10.13039\/501100010351","name":"Grosserer M. Brogaard og Hustrus Fond","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010351","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010344","name":"Aage og Johanne Louis-Hansens Fond","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010344","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,1,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>The effect of adjuvant therapy in node-negative pancreatic cancer is uncertain. The aim of this study was to estimate the effect of adjuvant chemotherapy on survival after surgery for pancreatic cancer in patients with node-negative (pN0) and node-positive (pN+) disease using target trial emulation.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This was an observational cohort study emulating a hypothetical RCT by the clone\u2013censor\u2013weight approach using population-based Danish healthcare registries. The study included Danish patients undergoing curative-intent surgery for pancreatic cancer during 2008\u20132021, who were discharged alive no more than 4 weeks after surgery. At the time of discharge after surgery, the data for each patient were duplicated; one copy was assigned to the adjuvant chemotherapy strategy and the other to the no adjuvant chemotherapy strategy of the hypothetical trial. Copies were censored when the assigned treatment was no longer compatible with the observed treatment. To account for informative censoring, uncensored patients were weighted according to measured confounders. The primary outcomes were absolute difference in 2-year survival and median overall survival, comparing adjuvant with no adjuvant chemotherapy.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Some 424 patients with pN0 and 953 with pN+ disease were included. Of these, 62.0 and 74.6% respectively initiated adjuvant chemotherapy within the 8-week grace period. Among patients with pN0 tumours, the difference in 2-year survival between those with and without adjuvant therapy was \u22122.2 (95% c.i. \u221211.8 to 7.4)%. In those with pN+ disease, the difference in 2-year survival was 9.9 (1.6 to 18.1)%. Median overall survival was 24.9 (i.q.r. 12.8\u201349.4) and 15.0 (8.0\u201334.0) months for patients having adjuvant and no adjuvant therapy respectively.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>In a target trial emulation using observational data, adjuvant chemotherapy did not improve survival after surgery for node-negative pancreatic cancer.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/bjs\/znad398","type":"journal-article","created":{"date-parts":[[2023,11,25]],"date-time":"2023-11-25T12:50:45Z","timestamp":1700916645000},"source":"Crossref","is-referenced-by-count":4,"title":["Effect of adjuvant chemotherapy after pancreatectomy in patients with node-negative pancreatic cancer: target trial emulation"],"prefix":"10.1093","volume":"111","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6994-0637","authenticated-orcid":false,"given":"Jakob","family":"Kirkeg\u00e5rd","sequence":"first","affiliation":[{"name":"Department of Surgery, Hepatopancreatobiliary Section, Aarhus University Hospital , Aarhus , Denmark"},{"name":"Department of Clinical Medicine, Aarhus University , Aarhus , Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0182-1228","authenticated-orcid":false,"given":"Morten","family":"Ladekarl","sequence":"additional","affiliation":[{"name":"Department of Oncology and Clinical Cancer Research Centre, Aalborg University Hospital , Aalborg , Denmark"},{"name":"Department of Clinical Medicine, Aalborg University , Aalborg , Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ida Ravnsb\u00e6k","family":"Johannsen","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine, Aarhus University , Aarhus , Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Mortensen","sequence":"additional","affiliation":[{"name":"Department of Surgery, Hepatopancreatobiliary Section, Aarhus University Hospital , Aarhus , Denmark"},{"name":"Department of Clinical Medicine, Aarhus University , Aarhus , Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,11,25]]},"reference":[{"key":"2024010617155273100_znad398-B1","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21654","article-title":"Cancer statistics, 2021","volume":"71","author":"Siegel","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"2024010617155273100_znad398-B2","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1001\/jama.2013.279201","article-title":"Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial","volume":"310","author":"Oettle","year":"2013","journal-title":"JAMA"},{"key":"2024010617155273100_znad398-B3","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1001\/jama.297.3.267","article-title":"Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial","volume":"297","author":"Oettle","year":"2007","journal-title":"JAMA"},{"key":"2024010617155273100_znad398-B4","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1001\/jamaoncol.2022.3829","article-title":"Five-year outcomes of FOLFIRINOX vs gemcitabine as adjuvant therapy for pancreatic cancer: a randomized clinical trial","volume":"8","author":"Conroy","year":"2022","journal-title":"JAMA Oncol"},{"key":"2024010617155273100_znad398-B5","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1056\/NEJMoa1809775","article-title":"FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer","volume":"379","author":"Conroy","year":"2018","journal-title":"N Engl J Med"},{"key":"2024010617155273100_znad398-B6","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1200\/JCO.22.01134","article-title":"Adjuvant nab-paclitaxel + gemcitabine in resected pancreatic ductal adenocarcinoma: results from a randomized, open-label, phase III trial","volume":"41","author":"Tempero","year":"2023","journal-title":"J Clin Oncol"},{"key":"2024010617155273100_znad398-B7","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/S0140-6736(16)30583-9","article-title":"Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01)","volume":"388","author":"Uesaka","year":"2016","journal-title":"Lancet"},{"key":"2024010617155273100_znad398-B8","doi-asserted-by":"crossref","first-page":"4004","DOI":"10.1245\/s10434-018-6763-4","article-title":"Clinical implications of extensive lymph node metastases for resected pancreatic cancer","volume":"25","author":"Lowder","year":"2018","journal-title":"Ann Surg Oncol"},{"key":"2024010617155273100_znad398-B9","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1016\/j.ejso.2013.07.089","article-title":"Number of examined lymph nodes and nodal status assessment in pancreaticoduodenectomy for pancreatic adenocarcinoma","volume":"39","author":"Vuarnesson","year":"2013","journal-title":"Eur J Surg Oncol"},{"key":"2024010617155273100_znad398-B10","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/S0140-6736(16)32409-6","article-title":"Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial","volume":"389","author":"Neoptolemos","year":"2017","journal-title":"Lancet"},{"key":"2024010617155273100_znad398-B11","doi-asserted-by":"crossref","first-page":"5881","DOI":"10.1002\/cam4.2491","article-title":"Adjuvant chemotherapy versus chemoradiation in high-risk pancreatic adenocarcinoma: a propensity score-matched analysis","volume":"8","author":"Raoof","year":"2019","journal-title":"Cancer Med"},{"key":"2024010617155273100_znad398-B12","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.pan.2022.03.008","article-title":"Adjuvant therapy for margin positive pancreatic cancer: a propensity score matched analysis","volume":"22","author":"Takahashi","year":"2022","journal-title":"Pancreatology"},{"key":"2024010617155273100_znad398-B13","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1007\/s12032-021-01469-y","article-title":"Real-world patterns of adjuvant chemotherapy treatment for patients with resected pancreatic adenocarcinoma","volume":"38","author":"Abdel-Rahman","year":"2021","journal-title":"Med Oncol"},{"key":"2024010617155273100_znad398-B14","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1001\/jamasurg.2022.5696","article-title":"Evaluation of adjuvant chemotherapy survival outcomes among patients with surgically resected pancreatic carcinoma with node-negative disease after neoadjuvant therapy","volume":"158","author":"Hammad","year":"2023","journal-title":"JAMA Surg"},{"key":"2024010617155273100_znad398-B15","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1001\/jamaoncol.2020.3537","article-title":"Evaluation of adjuvant chemotherapy in patients with resected pancreatic cancer after neoadjuvant FOLFIRINOX treatment","volume":"6","author":"van Roessel","year":"2020","journal-title":"JAMA Oncol"},{"key":"2024010617155273100_znad398-B16","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1245\/s10434-020-09543-x","article-title":"Clinical implication of node-negative resectable pancreatic cancer","volume":"28","author":"Yamada","year":"2021","journal-title":"Ann Surg Oncol"},{"key":"2024010617155273100_znad398-B17","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1001\/jamaoncol.2021.5407","article-title":"Patterns of adjuvant chemotherapy use and association with survival in adults 80 years and older with pancreatic adenocarcinoma","volume":"8","author":"Mehtsun","year":"2022","journal-title":"JAMA Oncol"},{"key":"2024010617155273100_znad398-B18","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.jclinepi.2016.04.014","article-title":"Specifying a target trial prevents immortal time bias and other self-inflicted injuries in observational analyses","volume":"79","author":"Hernan","year":"2016","journal-title":"J Clin Epidemiol"},{"key":"2024010617155273100_znad398-B19","doi-asserted-by":"crossref","first-page":"449","DOI":"10.2147\/CLEP.S91125","article-title":"The Danish National Patient Registry: a review of content, data quality, and research potential","volume":"7","author":"Schmidt","year":"2015","journal-title":"Clin Epidemiol"},{"key":"2024010617155273100_znad398-B20","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1177\/1403494810393562","article-title":"The Danish Cancer Registry","volume":"39","author":"Gjerstorff","year":"2011","journal-title":"Scand J Public Health"},{"key":"2024010617155273100_znad398-B21","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1007\/s10654-014-9930-3","article-title":"The Danish Civil Registration System as a tool in epidemiology","volume":"29","author":"Schmidt","year":"2014","journal-title":"Eur J Epidemiol"},{"key":"2024010617155273100_znad398-B22","doi-asserted-by":"crossref","first-page":"435","DOI":"10.2147\/CLEP.S99517","article-title":"The Danish Anaesthesia Database","volume":"8","author":"Antonsen","year":"2016","journal-title":"Clin Epidemiol"},{"key":"2024010617155273100_znad398-B23","doi-asserted-by":"crossref","first-page":"51","DOI":"10.2147\/CLEP.S9908","article-title":"Existing data sources for clinical epidemiology: the Danish National Pathology Registry and Data Bank","volume":"2","author":"Erichsen","year":"2010","journal-title":"Clin Epidemiol"},{"key":"2024010617155273100_znad398-B24","volume-title":"Documentation of the Register of Laboratory Results for Research","author":"Sundhedsdatastyrelsen"},{"key":"2024010617155273100_znad398-B25","volume-title":"AJCC Cancer Staging Handbook","author":"Edge","year":"2010","edition":"7th edn)"},{"key":"2024010617155273100_znad398-B26","doi-asserted-by":"crossref","first-page":"567","DOI":"10.2147\/CLEP.S353398","article-title":"Development and validation of a Nordic Multimorbidity Index based on hospital diagnoses and filled prescriptions","volume":"14","author":"Kristensen","year":"2022","journal-title":"Clin Epidemiol"},{"key":"2024010617155273100_znad398-B27","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1097\/SLA.0b013e3181b13ca2","article-title":"The Clavien\u2013Dindo classification of surgical complications: five-year experience","volume":"250","author":"Clavien","year":"2009","journal-title":"Ann Surg"},{"key":"2024010617155273100_znad398-B28","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1093\/ije\/dyaa057","article-title":"Reflection on modern methods: trial emulation in the presence of immortal-time bias. Assessing the benefit of major surgery for elderly lung cancer patients using observational data","volume":"49","author":"Maringe","year":"2020","journal-title":"Int J Epidemiol"},{"key":"2024010617155273100_znad398-B29","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1158\/1055-9965.EPI-22-0495","article-title":"The timing, the treatment, the question: comparison of epidemiologic approaches to minimize immortal time bias in real-world data using a surgical oncology example","volume":"31","author":"Duchesneau","year":"2022","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"2024010617155273100_znad398-B30","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1093\/aje\/kwv254","article-title":"Using big data to emulate a target trial when a randomized trial is not available","volume":"183","author":"Hernan","year":"2016","journal-title":"Am J Epidemiol"},{"key":"2024010617155273100_znad398-B31","doi-asserted-by":"crossref","first-page":"3661","DOI":"10.1002\/sim.6607","article-title":"Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies","volume":"34","author":"Austin","year":"2015","journal-title":"Stat Med"},{"key":"2024010617155273100_znad398-B32","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1245\/s10434-020-09043-y","article-title":"Undertreatment of pancreatic cancer: role of surgical pathology","volume":"28","author":"Olecki","year":"2021","journal-title":"Ann Surg Oncol"},{"key":"2024010617155273100_znad398-B33","doi-asserted-by":"crossref","first-page":"6790","DOI":"10.1245\/s10434-021-09823-0","article-title":"Adjuvant chemotherapy associated with survival benefit following neoadjuvant chemotherapy and pancreatectomy for pancreatic ductal adenocarcinoma: a population-based cohort study","volume":"28","author":"Kamarajah","year":"2021","journal-title":"Ann Surg Oncol"},{"key":"2024010617155273100_znad398-B34","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1093\/aje\/kwm324","article-title":"Immortal time bias in pharmaco-epidemiology","volume":"167","author":"Suissa","year":"2008","journal-title":"Am J Epidemiol"},{"key":"2024010617155273100_znad398-B35","doi-asserted-by":"crossref","first-page":"e42234","DOI":"10.1371\/journal.pone.0042234","article-title":"Rhot1 and smad4 are correlated with lymph node metastasis and overall survival in pancreatic cancer","volume":"7","author":"Jiang","year":"2012","journal-title":"PLoS One"},{"key":"2024010617155273100_znad398-B36","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1093\/annonc\/mdr617","article-title":"Contribution of CXCR4 and SMAD4 in predicting disease progression pattern and benefit from adjuvant chemotherapy in resected pancreatic adenocarcinoma","volume":"23","author":"Bachet","year":"2012","journal-title":"Ann Oncol"},{"key":"2024010617155273100_znad398-B37","doi-asserted-by":"crossref","first-page":"8482","DOI":"10.3748\/wjg.v20.i26.8482","article-title":"hENT1 expression is predictive of gemcitabine outcome in pancreatic cancer: a systematic review","volume":"20","author":"Nordh","year":"2014","journal-title":"World J Gastroenterol"},{"key":"2024010617155273100_znad398-B38","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1007\/s10147-012-0474-9","article-title":"Performance status of patients is the major prognostic factor at all stages of pancreatic cancer","volume":"18","author":"Tas","year":"2013","journal-title":"Int J Clin Oncol"}],"container-title":["British Journal of Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/bjs\/article-pdf\/111\/1\/znad398\/55122387\/znad398.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjs\/article-pdf\/111\/1\/znad398\/55122387\/znad398.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,6]],"date-time":"2024-01-06T17:16:10Z","timestamp":1704561370000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjs\/article\/doi\/10.1093\/bjs\/znad398\/7450979"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,25]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,11,25]]},"published-print":{"date-parts":[[2024,1,3]]}},"URL":"https:\/\/doi.org\/10.1093\/bjs\/znad398","relation":{},"ISSN":["0007-1323","1365-2168"],"issn-type":[{"value":"0007-1323","type":"print"},{"value":"1365-2168","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,1]]},"published":{"date-parts":[[2023,11,25]]},"article-number":"znad398"}}